⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721399 | 1.00 | — | — | |
| SCHEMBL3721400 | 1.00 | — | — | |
| SCHEMBL14302345 | 1.00 | — | — | |
| SCHEMBL4555410 | 1.00 | — | — | |
| SCHEMBL27397 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1569361 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL7594425 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL4622071 | 0.96 | CCR5 (0.53) | — | |
| Hydrochloric Acid SCHEMBL1570941 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL27743708 | 0.93 | CCR5 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307419-B1 | BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS | CODEXIS INC (US) | 2013-11-06 | — | — | EP | claimed |
| US-8178333-B2 | Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds | CODEXIS, INC. (US) | 2012-05-15 | — | — | US | claimed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-09 | — | — | US | disclosed |
| US-12006307-B2 | Pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1781656-B1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| WO-2007022459-A2 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| US-4691022-A | Process for the preparation of monocyclic, bicyclic and tricyclic aminoacids | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | disclosed |
| EP-0132580-A1 | Process for the preparation of mono, bi and tricyclic aminoacids | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-02-13 | — | — | EP | disclosed |